The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
(2021) In npj Breast Cancer 7(1).- Abstract
- The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group,... (More)
- The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/f208bf2b-2108-4200-9cec-b47449aec8ca
- author
- author collaboration
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- npj Breast Cancer
- volume
- 7
- issue
- 1
- article number
- 150
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85120908291
- pmid:34853355
- ISSN
- 2374-4677
- DOI
- 10.1038/s41523-021-00346-1
- language
- English
- LU publication?
- yes
- id
- f208bf2b-2108-4200-9cec-b47449aec8ca
- date added to LUP
- 2021-12-01 23:58:40
- date last changed
- 2022-04-27 06:11:16
@article{f208bf2b-2108-4200-9cec-b47449aec8ca, abstract = {{The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.}}, author = {{El Bairi, Khalid and Haynes, Harry R. and Blackley, Elizabeth and Fineberg, Susan and Shear, Jeffrey and Turner, Sophia and De Freitas, Juliana Ribeiro and Sur, Daniel and Amendola, Luis Claudio and Gharib, Masoumeh and Kallala, Amine and Arun, Indu and Azmoudeh-ardalan, Farid and Fujimoto, Luciana and Sua, Luz F. and Liu, Shi-wei and Lien, Huang-chun and Kirtani, Pawan and Balancin, Marcelo and El Attar, Hicham and Guleria, Prerna and Yang, Wenxian and Shash, Emad and Chen, I-chun and Bautista, Veronica and Do Prado Moura, Jose Fernando and Rapoport, Bernardo L. and Castaneda, Carlos and Spengler, Eunice and Acosta-haab, Gabriela and Frahm, Isabel and Sanchez, Joselyn and Castillo, Miluska and Bouchmaa, Najat and Md Zin, Reena R. and Shui, Ruohong and Onyuma, Timothy and Yang, Wentao and Husain, Zaheed and Willard-gallo, Karen and Coosemans, An and Perez, Edith A. and Provenzano, Elena and Ericsson, Paula Gonzalez and Richardet, Eduardo and Mehrotra, Ravi and Ehinger, Anna and Brown, Mark and Lundin, Johan and Loi, Sherene}}, issn = {{2374-4677}}, language = {{eng}}, number = {{1}}, publisher = {{Nature Publishing Group}}, series = {{npj Breast Cancer}}, title = {{The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group}}, url = {{http://dx.doi.org/10.1038/s41523-021-00346-1}}, doi = {{10.1038/s41523-021-00346-1}}, volume = {{7}}, year = {{2021}}, }